Evropská unie - čeština - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamid - prostatetické novotvary - endokrinní terapie - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

sandoz s.r.o., praha array - 19795 enzalutamid - potahovaná tableta - 40mg - enzalutamid

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

sandoz s.r.o., praha array - 19795 enzalutamid - potahovaná tableta - 80mg - enzalutamid